Navigation Links
New anti-HIV gene therapy makes T-cells resistant to HIV infection
Date:1/26/2011

New Rochelle, NY, January 26, 2011An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a paper published in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The paper is available free online at www.liebertpub.com/hum

A team of researchers from Japan, Korea, and the U.S. developed an anti-HIV gene therapy method in which a bacterial gene called mazF is transferred into CD4+ T-cells. The MazF protein is an enzyme (an mRNA interferase) that destroys gene transcripts, preventing protein synthesis. The design of this mazF gene therapy vector ensures that synthesis of the MazF protein is triggered by HIV infection. When HIV infects treated T lymphocytes, MazF is induced, blocking HIV replication and, essentially, making the T-cells HIV resistant.

This elegant gene therapy tool was developed by Hideto Chono and colleagues from Takara Bio Inc. (Otsu, Shiga, Japan), Seoul National University and ViroMed Co. (Seoul, Korea), National Institute of Biomedical Innovation (Tsukuba, Ibaraki, Japan), and Robert Wood Johnson Medical School (Piscataway, NJ). The authors describe the theory and science behind this strategy in the paper entitled, "Acquisition of HIV-1 Resistance in T Lymphocytes Using an ACA-Specific E. coli mRNA Interferase."

"The potential of using vectors to express genes within a cell to block viral infection was first considered by David Baltimore in a strategy called 'intracellular immunization.' This study illustrates a unique way in which intracellular immunization can be achieved," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Researchers report on the early development of anti-HIV neutralizing antibodies
2. Designing more effective anti-HIV antibodies
3. Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
4. Einstein to develop anti-HIV drug delivery system
5. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
6. Bodys anti-HIV drug explained
7. Caffeine energizes cells, boosting virus production for gene therapy applications
8. Nanodisk gene therapy
9. Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy
10. New breathing therapy reduces panic and anxiety by reversing hyperventilation
11. Missing molecules hold promise of therapy for pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New anti-HIV gene therapy makes T-cells resistant to HIV infection
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: